Selected anticipated grade 3 or greater adverse events within 30 days of start of treatment
| Adverse event . | Overall (N = 280) . | IVO with AZA/DEC (n = 181) . | VEN with AZA/DEC (n = 99) . | P value . | |||
|---|---|---|---|---|---|---|---|
| n . | % . | n . | % . | n . | % . | ||
| Febrile neutropenia, grade ≥3 | 11 | 3.9 | 3 | 1.7 | 8 | 8.1 | .0082 |
| Sepsis | 3 | 1.1 | 1 | 0.6 | 2 | 2.0 | .2541 |
| Infection, grade ≥3 | 5 | 1.8 | 3 | 1.7 | 2 | 2.0 | .8266 |
| Pneumonia, grade ≥3 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | — |
| Neutropenia, grade ≥3 | 14 | 5.0 | 7 | 3.9 | 7 | 7.1 | .2397 |
| Thrombocytopenia, grade ≥3 | 15 | 5.4 | 8 | 4.4 | 7 | 7.1 | .3463 |
| Leukocytosis, grade ≥3 | 2 | 0.7 | 1 | 0.6 | 1 | 1.0 | .6638 |
| Differentiation syndrome | 1 | 0.4 | 1 | 0.6 | 0 | 0.0 | — |
| None of the above | 251 | 89.6 | 165 | 91.2 | 86 | 86.9 | .2599 |
| Adverse event . | Overall (N = 280) . | IVO with AZA/DEC (n = 181) . | VEN with AZA/DEC (n = 99) . | P value . | |||
|---|---|---|---|---|---|---|---|
| n . | % . | n . | % . | n . | % . | ||
| Febrile neutropenia, grade ≥3 | 11 | 3.9 | 3 | 1.7 | 8 | 8.1 | .0082 |
| Sepsis | 3 | 1.1 | 1 | 0.6 | 2 | 2.0 | .2541 |
| Infection, grade ≥3 | 5 | 1.8 | 3 | 1.7 | 2 | 2.0 | .8266 |
| Pneumonia, grade ≥3 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | — |
| Neutropenia, grade ≥3 | 14 | 5.0 | 7 | 3.9 | 7 | 7.1 | .2397 |
| Thrombocytopenia, grade ≥3 | 15 | 5.4 | 8 | 4.4 | 7 | 7.1 | .3463 |
| Leukocytosis, grade ≥3 | 2 | 0.7 | 1 | 0.6 | 1 | 1.0 | .6638 |
| Differentiation syndrome | 1 | 0.4 | 1 | 0.6 | 0 | 0.0 | — |
| None of the above | 251 | 89.6 | 165 | 91.2 | 86 | 86.9 | .2599 |